Stocks · Healthcare · Biotechnology
Fennec Pharmaceuticals Inc. FENC
$10.20 -1.26% Close, Oct 2, 2026 · NASDAQ · Market cap $354.3M
Strong growth
Next earnings report: Nov 12, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Revenue over the last four quarters was $59.2M, up 77.8% from a year earlier, accelerating from 65.0% a quarter earlier.
- Operating margin widened to -2.0% from -29.2% a year earlier.
- The diluted share count rose 31.7% in a year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 12%
- Revenue growth, 3-year CAGRTop 3%
- Revenue growth accelerationTop 11%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 34%
- Gross marginTop 15%
- Operating marginTop 44%
- Accruals (lower is better)Bottom 21%
- Interest coverTop 49%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 33%
- Free-cash-flow yieldTop 37%
- EBITDA / enterprise valueTop 40%
- Sales / enterprise valueBottom 46%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 45%
- 6-month returnTop 17%
- 1-year return vs S&P 500Bottom 47%
- Distance from 52-week highTop 36%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 11%
- Consecutive EPS beatsTop 35%
- Share of analysts rating BuyTop 10%
- Upside to consensus price targetBottom 48%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 43%
- Maximum drawdown, 3 yearsTop 43%
- Beta vs S&P 500 (lower is better)Bottom 25%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 65.0% | 77.8% | ↑ |
| Gross margin | 89.9% | 93.7% | ↑ |
| Operating margin | -29.2% | -2.0% | ↑ |
| FCF margin | -35.1% | -3.4% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 77.8% | 65.0% | ↑ | Top 12% |
| Gross margin | 93.7% | 89.9% | ↑ | Top 15% |
| Operating margin | -2.0% | -29.2% | ↑ | Top 44% |
| Net margin | -5.5% | -36.1% | ↑ | — |
| Free-cash-flow margin | -3.4% | -35.1% | ↑ | — |
| Return on invested capital | -1.8% | — | Top 34% | |
| Revenue growth, 3-year CAGR | 207.5% | — | Top 3% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -1.6%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 11.0%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -44.9 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -1.3×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -13.01%
- Shareholder yield
- -13.01%
- Share count change, 1 year
- +31.7%
- Share count change, 3-year CAGR
- +11.3%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 13, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 2
- Beats in the last 8 reports
- 4 of 8
- Average EPS surprise, last 4
- -72.9%
- Average 2-day reaction, last 8
- +0.9%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $16.00
- Target vs current price
- +56.9%
- Analysts with a rating
- 8
- Share rating Buy or Strong Buy
- 100%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 11, 2026 | +150.0% | +16.8% | +8.1% | +13.8% | — |
| May 14, 2026 | +150.0% | +36.5% | +44.0% | +30.7% | +61.6% |
| Mar 24, 2026 | -666.7% | -19.2% | -22.6% | -12.2% | +20.5% |
| Nov 13, 2025 | +75.0% | -1.2% | +5.1% | -3.7% | +0.1% |
| Aug 14, 2025 | -83.3% | -6.4% | -11.3% | -0.9% | -12.2% |
| May 13, 2025 | +66.7% | +3.3% | +22.0% | +32.5% | +28.7% |
| Mar 10, 2025 | -110.7% | -11.2% | -5.4% | -23.7% | +14.5% |
| Nov 7, 2024 | -61.5% | -11.9% | -9.5% | +15.6% | +37.2% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 11, 2026 | $0.05 | $0.02 | +150.0% | $17.9M |
| May 14, 2026 | $0.01 | -$0.02 | +150.0% | $15.1M |
| Mar 24, 2026 | -$0.17 | $0.03 | -666.7% | $13.8M |
| Nov 13, 2025 | -$0.02 | -$0.08 | +75.0% | $12.5M |
| Aug 14, 2025 | -$0.11 | -$0.06 | -83.3% | $9.7M |
| May 13, 2025 | -$0.04 | -$0.12 | +66.7% | $8.8M |
| Mar 10, 2025 | -$0.06 | $0.56 | -110.7% | $7.9M |
| Nov 7, 2024 | -$0.21 | -$0.13 | -61.5% | $7.0M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (forward) | 36.0× | — | — | — |
| EV / Sales | 5.29× | — | — | Bottom 46% |
| Free-cash-flow yield | -0.58% | — | — | Top 37% |
| Earnings yield | -1.35% | — | — | Top 33% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 98
- 50-day average slope (20 days)
- +1.4%
- 200-day average slope (20 days)
- +3.6%
- Distance from 50-day average
- -8.4%
- Distance from 200-day average
- +14.2%
- RSI (14)
- 38.1
- Relative volume
- 0.76×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 59.2%
- Volatility vs own 5-year history
- 70th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.68
- Correlation with S&P 500
- 0.40
- Current drawdown from 1-year high
- -20.2%
- Maximum drawdown, 3 years
- -65.6%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Dec 28, 2023 | Nov 15, 2024 | -65.6% | 223 days | 432 days (Aug 11, 2026) |
| Nov 22, 2021 | Dec 1, 2021 | -61.1% | 6 days | 260 days (Dec 13, 2022) |
| Jan 13, 2023 | Oct 5, 2023 | -37.4% | 182 days | 53 days (Dec 20, 2023) |
| Feb 9, 2021 | May 4, 2021 | -31.3% | 58 days | 91 days (Sep 13, 2021) |
| Aug 11, 2026 | Oct 2, 2026 | -20.2% | 37 days | Not yet recovered |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $354.3M
- EPS, diluted (TTM)
- -$0.14
- Revenue (TTM)
- $59.2M
- 52-week range
- $5.65 – $13.25
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $1.5M | $21.3M | $47.5M | $44.6M |
| Gross profit | $0 | $1.4M | $20.0M | $44.4M | $40.9M |
| Operating income | -$17.2M | -$22.7M | -$13.1M | $2.5M | -$6.3M |
| Net income | -$17.3M | -$23.7M | -$16.0M | -$436,000 | -$9.7M |
| EPS (diluted) | -$0.67 | -$0.95 | -$0.60 | -$0.02 | -$0.36 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.0M | $7.9M | $8.8M | $9.7M | $12.5M | $13.8M | $15.1M | $17.9M |
| Net income | -$5.7M | -$2.0M | -$1.2M | -$3.2M | -$638,000 | -$4.8M | $201,000 | $2.0M |
| EPS (diluted) | -$0.21 | -$0.06 | -$0.04 | -$0.12 | -$0.02 | -$0.17 | $0.01 | $0.05 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$14.2M | -$18.1M | -$17.1M | $27.0M | -$12.5M |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 |
| Free cash flow | -$14.2M | -$18.1M | -$17.1M | $27.0M | -$12.5M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $33,000 | -$194,000 | -$78,000 | -$176,000 | $45.0M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $41.2M
- Total assets
- $75.8M
- Total liabilities
- $33.3M
- Total debt
- $0
- Net debt
- -$41.2M
- Shareholders’ equity
- $42.4M
As of Jun 30, 2026 (filed Aug 13, 2026).
Short interest
- Shares sold short
- 545,039
- Days to cover
- 2.11
- Change vs previous report
- +4.7%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Sep 9, 2014
- 1-for-3
- Aug 31, 2011
- 1-for-18
- Aug 2, 2005
- 1-for-5